Security key
097702203
Bolt Biotherapeutics, Inc. - Common Stock, $0.00001 par value (BOLT)
CUSIP: 097702203
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, $0.00001 par value
- Total 13F shares
- 38,171
- Total 13F value
- $146,959
- Share change
- +161
- SEC-reported price per share
- $3.85
- Number of holders
- 3
- Value change
- +$620
- Number of buys
- 2
- Shares outstanding
- 1,901,870
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
3
Top holders
3
BOLT full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Bolt Biotherapeutics, Inc. SEC filings
Bolt Biotherapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 097702203
Recent filing periods:
Ownership snapshot
Top reported holders of BOLT - Bolt Biotherapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Pivotal bioVenture Partne...
Disclosed value leader
Sofinnova Investments, Inc.
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
13F
Lead comparable stake: 4.6%
13D/G row: Pivotal bioVenture Partners Fund I, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Pivotal bioVenture Partners Fund I, L.P. leads the comparable SEC ownership view at 4.6%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Pivotal bioVenture Partners Fund I, L.P.'s linked filing trail.
Comparable ownership
Top 5
Pivotal bioVenture Partners Fund ...
4.6%
TANG CAPITAL MANAGEMENT LLC
3.5%
Sofinnova Investments, Inc.
7.2%
RENAISSANCE TECHNOLOGIES LLC
4.1%
Vivo Capital, LLC
3.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Pivotal bioVenture Partners Fund I, L.P. |
13D/G
Nan Fung Group Holdings Limited
|
4.6%
|
$478,373
87,486 shares
|
-$222,181 | 24 Feb 2026 |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
|
3.5%
|
$355,790
66,879 shares
|
-$531,990 | 30 Sep 2025 |
| Sofinnova Investments, Inc. |
13F
Company
|
7.2%
|
$556,393
137,721 shares
|
— | 31 Mar 2026 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
4.1%
|
$311,989
77,225 shares
|
— | 31 Mar 2026 |
| Vivo Capital, LLC |
13F
Company
|
3.8%
|
$292,553
72,414 shares
|
— | 31 Mar 2026 |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
Company
|
2.2%
|
$172,027
42,581 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
38,171
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
24
Q2 2026 holders
3
Holder diff
-21
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend